Immune-Mediated Inflammatory Disease Forum

Secukinumab, an IL-17A monoclonal antibody, was shown to have remarkable efficacy for axSpA in the MEASURE 2 and MEASURE 3 trials. Previous studies have concluded that secukinumab was more efficacious in TNFi-naïve patients.

Keywords:

生物学的または分子標的抗リウマチ薬治療中の関節リウマチ患者の間質性肺疾患の罹患率

JAMA Netw Open. 2023;6(3):e233640 doi: 10.1001/jamanetworkopen.2023.3640

Baker MC,

Liu Y,

Lu R,

Lin J,

Melehani J,

Robinson WH

Retrospective cohort study results suggest that treatment with tofacitinib, and perhaps other JAK inhibitors, may provide a benefit in reducing the risk of developing RA-Interstitial Lung Disease (ILD).

Keywords:

強直性脊椎炎患者における８年間のNSAIDs使用が主要血管イベントに与える影響：ナショナルデータ

Rheumatology (Oxford). 2023 doi: 10.1093/rheumatology/kead072

Fakih O,

Prati C,

MACEs were observed in patients newly receiving compensation from the Long-term Illness Scheme for AS. The objective of this study was to describe the incidence of MACEs in French patients newly benefiting from the French LTI for AS. The study also sought to evaluate the effect of various treatments on the risk of MACE occurrence.

Keywords:

関節リウマチ、乾癬性関節炎、強直性脊椎炎を対象とした１５０００人年におよぶウパダシチニブの安全性

RMD Open. 2023;9(1):e002735 doi: 10.1136/rmdopen-2022-002735

Nash P,

Liu J,

Palac H,

Shaw T,

Mease PJ,

Guttman-Yassky E

Integrated analysis of the safety profile of upadacitinib demonstrates that it was generally well-tolerated in RA, PsA, AS and AD, with no new safety risks identified, compared with previous reports.

Keywords:

リスク保有患者におけるバリシチニブの安全性: リウマチおよび皮膚科領域の臨床試験解析

Adv Ther. 2023;40(4):1867–1883 doi: 10.1007/s12325-023-02445-w

Taylor PC,

Bieber T,

Alten R,

Witte T,

Issa M,

Grond S,

Analysis of pooled data from the baricitinib clinical development programmes finds a low incidence rate of MACE, myocardial infarction, lung cancer, VTE, and overall mortality in patients <65 years without risk factors.

Keywords:

実臨床での関節リウマチに用いる生物製剤および分子標的合成抗リウマチ薬の安全性: ARTIS プログラムからのデータ

Ann Rheum Dis. 2023;82(5):601–610 doi: 10.1136/ard-2022-223762

Frisell T,

Bower H,

Morin M,

Askling J; ARTIS Study group.

Nationwide register-based cohort study corroborates and extends previous evidence that the currently available biologic/targeted synthetic DMARDs have an acceptable and, on the whole, similar safety profile.

Keywords:

トファシチニブ, バリシチニブ, ウパダシチニブで治療された炎症性関節炎および潰瘍性大腸炎患者の帯状疱疹: 臨床試験と実臨床データのシステマティックレビュー

Overall, this evidence supports that HZ-risk is a “class” effect of JAKi, observing a higher risk compared to other non-biologic/biologic drugs . This study aimed to systematically review the incidence of HZ among RA, PsA, AS and UC patients treated with TOFA, BARI or UPA.

Overall, this evidence supports that HZ-risk is a “class” effect of JAKi, observing a higher risk compared to other non-biologic/biologic drugs . This study aimed to systematically review the incidence of HZ among RA, PsA, AS and UC patients treated with TOFA, BARI or UPA.